Internship, Good Samaritan Hospital, Portland, OR. I am actively involved in designing and developing clinical research studies at the Swedish Cancer Institute and through national research organizations, including the Southwestern Oncology Group. I have written several articles evaluating the use of concurrent chemotherapy and radiation in the management of malignancy and presented our findings at national and international meetings.

American Society of Therapeutic Radiation Oncologists
American Association of Indian Physicians
American Society of Clinical Oncology
Washington State Radiation Oncology Society (Scientific Program Chair, 2003 – Present)

Dr. Mehta was voted "Top Doctors" in Seattle Magazine (2014).

Surveys were mailed to physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.

I enjoy working with patients and family members. There are a wide variety of treatment options available for nearly every patient, so it is important to spend as much time as is needed in order to weigh the benefits and risks to any particular approach. In certain cases, we use techniques that we have perfected over the years and for other patients we use newer more investigational or "cutting-edge" approaches. I think it is important that communication is open and honest. The goals of treatment, whether it is going for "cure" or maximizing "quality of life," should be openly discussed and rediscussed as the need arises.

Medical School

University of Washington- Seattle, WA

Residency

Stanford University Medical Center, Stanford, CA

Board Certifications

Therapeutic Radiology

Additional Information:

Internship, Good Samaritan Hospital, Portland, OR. I am actively involved in designing and developing clinical research studies at the Swedish Cancer Institute and through national research organizations, including the Southwestern Oncology Group. I have written several articles evaluating the use of concurrent chemotherapy and radiation in the management of malignancy and presented our findings at national and international meetings.

American Society of Therapeutic Radiation Oncologists
American Association of Indian Physicians
American Society of Clinical Oncology
Washington State Radiation Oncology Society (Scientific Program Chair, 2003 – Present)

Dr. Mehta was voted "Top Doctors" in Seattle Magazine (2014).

Surveys were mailed to physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.

Patients that I see routinely ask me about the heart related side effects from breast treatment.

Today, I can provide them with even greater evidence that the techniques that we use today are safer and have less risk of cardiac injury. According to a study published in the October 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO), the survival from breast cancer is the same regardless of whether you were treated with radiation to your left or right breast mound.

Many studies over many decades have shown that breast cancer patients treated with radiation therapy have improved local-regional recurrence, and breast cancer-specific survival after breast-conserving surgery and overall survival (OS) after mastectomy. The media has focused its attention on long-term follow-up of historic radiation therapy trials for breast cancer which demonstrated a potential increase in cardiac mortality. However, these studies used earlier modes of radiation therapy including Cobalt and orthovoltage radiotherapy, and did not employ CT-based planning, which allows for greater cardiac avoidance. Three recent studies suggest that ....

This observation and debate has been ongoing for a long time in medical literature. Most recently, an article in the New England Journal of Medicine concluded that adjuvant radiotherapy for breast cancer increases the rate of ischemic heart disease. The authors conclude that the risk is associated with the dose of radiotherapy to the heart and begins a few years after the treatment. Dr. Kesarwala, an expert radiation oncologist from Bethesda, reviewed the data and provided a report in the April issue of the ACR Journal Advisor. She noted that “nearly 80% of patients in this study had mastectomies and over 90% had adjuvant chemotherapy with regimens very different from those currently used. This study mixed lymph node-positive patients (48%) with lymph node-negative patients, two sub-populations with different expected overall survival who would also have received different types of radiotherapy.” Other variables such as stage, presence of internal mammary nodes, type of surgery, or details of radiotherapy were not matched between the control and treated patients.

Because the study does not provide details regarding the radiotherapy specifically, it is difficult to interpret the conclusions. The doses of radiotherapy delivered ...

Stereotactic Ablative Radiotherapy is a new term that has been coined to describe the delivery of very high doses of radiation delivered over a handful of treatment sessions. This precise method targets small tumors located in the lung. This new treatment has been pioneered and studied extensively in patients who are not suitable candidates for an operation but have been diagnosed with early stage Non-Small Cell Lung Cancer.

The advantages of this approach are that the treatment can be completed in 1-2 weeks (including the planning time), and only requires 3-5 treatments. The treatment requires highly specialized planning and preparation and is delivered using state of the art linear accelerators like the CyberKnife®. Our team has been offering stereotactic ablative radiotherapy for over 4 years.

The results are outstanding for this population of patients. A number of studies have demonstrated that the local tumor control rates exceed ...